- In February 2025, Avitia launched an AI-powered cancer diagnostics platform, enabling rapid, cost-effective testing at the point of care. This innovation enhances clinical decision-making, reduces costs, and accelerates treatment timelines. Already deployed across North America and Southeast Asia, Avitia’s platform advances precision oncology
- In January 2025, Roche received FDA 510(k) clearance and a CLIA waiver for its cobas liat multiplex assays, enabling point-of-care STI testing. These assays allow clinicians to diagnose chlamydia, gonorrhea, and Mycoplasma genitalium using a single sample, delivering results in 20 minutes. The technology enhances rapid treatment decisions and reduces follow-up delays
- In May 2025, Sherlock Bio has begun clinical trials for its over-the-counter rapid STI test, designed to detect chlamydia and gonorrhea with self-collected swabs. The test delivers results within 30 minutes, improving accessibility and reducing discomfort compared to traditional lab testing. The company aims for a mid-2025 launch, pending FDA approval
- In May 2024, Molbio launched TruSight, an AI-powered point-of-care platform for hematology applications, including complete blood count (CBC), malaria detection, and sickle cell disease screening. Designed for resource-limited settings, TruSight enhances diagnostic accuracy and accessibility, supporting rapid blood analysis with advanced AI algorithms. This innovation aims to improve clinical efficiency while reducing testing barriers
- In December 2024, Labcorp introduced a molecular diagnostic test for the H5N1 bird flu virus, supporting rapid detection amid a multistate outbreak in the U.S. The test, developed with CDC collaboration, enhances public health preparedness by enabling physicians to diagnose infections quickly using nasopharyngeal swabs
